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Abstract
Methylphenidate and 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) are widely misused psycho-
active drugs. Methylphenidate increases brain dopamine and norepinephrine levels by blocking the presynaptic
reuptake transporters. MDMA releases serotonin, dopamine and norepinephrine through the same transporters.
Pharmacodynamic interactions of methylphenidate and MDMA are likely. This study compared the pharmaco-
dynamic and pharmacokinetic effects of methylphenidate and MDMA administered alone or in combination in
healthy subjects using a double-blind, placebo-controlled, crossover design. Methylphenidate did not enhance
the psychotropic effects of MDMA, although it produced psychostimulant effects on its own. The haemodynamic
and adverse effects of co-administration of methylphenidate and MDMA were significantly higher compared
with MDMA or methylphenidate alone. Methylphenidate did not change the pharmacokinetics of MDMA
and vice versa. Methylphenidate and MDMA shared some subjective amphetamine-type effects; however,
125mg of MDMA increased positive mood more than 60mg of methylphenidate, and methylphenidate
enhanced activity and concentration more than MDMA. Methylphenidate and MDMA differentially altered
facial emotion recognition. Methylphenidate enhanced the recognition of sad and fearful faces, whereas
MDMA reduced the recognition of negative emotions. Additionally, the present study found acute pharmaco-
dynamic tolerance to MDMA but not methylphenidate. In conclusion, the combined use of methylphenidate
and MDMA does not produce more psychoactive effects compared with either drug alone, but potentially
enhances cardiovascular and adverse effects. The findings may be of clinical importance for assessing
the risks of combined psychostimulant misuse. Trial registration identification number: NCT01465685 (http://
clinicaltrials.gov/ct2/show/NCT01465685).
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Introduction
Methylphenidate is used for the treatment of attention-
deficit/hyperactivity disorder and misused as a cognitive
enhancer and recreationally (McCabe et al., 2005). 3,4-
methylenedioxymethamphetamine (MDMA; ‘ecstasy’) is
a popular recreational drug. People who frequently use
ecstasy often also use methylphenidate (Wilkins et al.,
2011). Methylphenidate inhibits the dopamine (DA) and
norepinephrine (NE) transporters (DAT and NET) (Han
and Gu, 2006), thereby elevating DA and NE levels in
the brain (Schmeichel and Berridge, 2013). MDMA re-
leases brain serotonin (5-hydroxytryptamine (5-HT)),
NE and DA through their corresponding reuptake trans-
porters (Verrico et al., 2007; Hysek et al., 2012d). Because
both methylphenidate and MDMA act at the DAT and
NET, pharmacodynamic drug–drug interactions can be
expected, but have not been evaluated. Therefore, the
present clinical study assessed the pharmacodynamic
and pharmacokinetic interactions between methylpheni-
date and MDMA in healthy volunteers.
MDMA-induced monoamine release is blocked by
monoamine transporter inhibitors (Verrico et al., 2007;
Rothman et al., 2010; Hysek et al., 2012d). Inhibition of
the 5-HT transporter (SERT) (Liechti et al., 2000; Farre
et al., 2007) or NET (Hysek et al., 2011) attenuated the
pharmacodynamic response to MDMA in healthy sub-
jects. Whether the DAT contributes to the effects of
MDMA in humans has not yet been tested. Methyl-
phenidate inhibits the transport of MDMA into cells
and MDMA-induced release of DA and NE (Verrico
et al., 2008; Hysek et al., 2012d). We hypothesized that
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methylphenidate may attenuate the emotional, auto-
nomic and endocrine effects of MDMA to the extent
that they depend on the DAT/NET-mediated release of
DA/NE. We did not anticipate any pharmacokinetic
methylphenidate-MDMA interactions because methyl-
phenidate is metabolized by carboxylesterase 1 (Sun
et al., 2004), and MDMA is primarily metabolized by
cytochrome P450 (CYP) 2D6 (de la Torre et al., 2012).
Thus, we expected pharmacodynamic methylphenidate-
MDMA interactions in the absence of pharmacokinetic
interactions.
Additionally, the present study directly compared
the emotional, autonomic, endocrine and pharmacologi-
cal effects of methylphenidate and MDMA in the same
subjects.
Methods
Participants
Sixteen healthy subjects (eight men and eight women;
mean age 24.8±2.6 yr) were recruited from the University
of Basel campus. Subjects with a personal or first-degree
relative history of psychiatric disorders or chronic or
acute physical illness were excluded as previously
described (Hysek et al., 2012b, c). Additional exclusion
criteria were smoking and a lifetime history of using illicit
drugs more than five times, with the exception of past
cannabis use. Thirteen subjects had used cannabis at
some time in their lives. Eleven subjects had minimal pre-
vious experience with other illicit drugs (2–4 times).
Six subjects had used ecstasy, three had used a stimulant,
one had used an hallucinogen and three had used nitrous
oxide. The use of any illicit drugs, including cannabis,
within the past two months or during the study period
was prohibited. We performed urine drug tests at screen-
ing and before each test session using TRIAGE 8 (Biosite,
USA). Female participants were investigated during
the follicular phase of their menstrual cycle (day 2–14)
to account for cyclic changes in the reactivity to amphet-
amines. Because MDMA is metabolized primarily by
CYP2D6, all of the subjects, with the exception of one,
were phenotyped for CYP2D6 activity using dextro-
methorphan as the probe drug. The study had 12 ex-
tensive, two intermediate, and one poor CYP2D6
metabolizer.
Study design
This was a double-blind, placebo-controlled, cross-over
study with four experimental test sessions (placebo–
placebo, methylphenidate–placebo, placebo–MDMA,
and methylphenidate–MDMA) performed in randomized
and counterbalanced order. This means that all of the
subjects received all of the study treatments in a powerful
within-subjects study design. The washout periods be-
tween sessions were at least 10 d. The study was conduc-
ted at the University Hospital of Basel in accordance with
the Declaration of Helsinki and International Conference
on Harmonization Guidelines in Good Clinical
Practice and approved by the Ethics Committee of the
Canton of Basel, Switzerland, and the Swiss Agency for
Therapeutic Products (Swissmedic). The study was regis-
tered at ClinicalTrials.gov (http://clinicaltrials.gov/ct2/
show/NCT01465685). All of the subjects provided written
informed consent and were debriefed and paid at study
completion.
Study outline
The study included a prescreening telephone interview, a
screening visit, four whole-day test sessions with a next-
day follow-up and an end-of-study visit. Study sessions
began at 07:45 hours. An indwelling intravenous catheter
was placed in an antecubital vein for blood sampling,
and baseline measurements were performed. Methyl-
phenidate (60mg) or placebo was administered at
08:00 hours. MDMA (125mg) or placebo was adminis-
tered at 09:00 hours. A standardized lunch was served
at 12:00 hours, and the subjects were sent home at
18:00 hours. On the day following each test session,
the participants returned to the research ward at
09:00 hours for the assessment of adverse effects and
blood sampling. The sessions occurred in a hospital re-
search ward with a maximum of two participants present
per session. The subjects sat or laid comfortably and did
not engage in physical activities.
Drugs
±MDMA hydrochloride (Lipomed AG, Switzerland) was
prepared as gelatin capsules (100 and 25mg). Identical
placebo (mannitol) capsules were prepared. MDMA was
administered in a single absolute dose of 125mg, corre-
sponding to 1.87±0.21mg/kg body weight (mean±S.D.).
Immediate-release methylphenidate tablets (10mg,
Ritalin, Novartis AG, Switzerland) were encapsulated
within opaque gelatin capsules, and identical placebo
(mannitol) capsules were prepared. One hour before
MDMA administration, methylphenidate was adminis-
tered in a single dose of 60mg, corresponding to 0.90±
0.1 mg/kg body weight (mean±S.D.). This dosing interval
resulted in maximal plasma concentration (Cmax) values
of methylphenidate shortly before the Cmax of MDMA
was reached.
Measures
Pharmacodynamics
Autonomic effects. Blood pressure, heart rate and tympanic
body temperature were assessed repeatedly before and
0, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6 and 8 h after MDMA/
placebo administration, as previously described in detail
(Hysek and Liechti, 2012). The cardiovascular measures
were performed in duplicate after a resting time of 10min
and the averages were used for the analyses.
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Psychometric scales. Subjective effects were repeatedly
assessed using previously described psychometric
scales. The 60-item short version of the Adjective Mood
Rating Scale (AMRS; Janke and Debus, 1978) was
administered before and 1.25, 2, 5 and 24 h after
MDMA/placebo administration. The German version of
the 49-item Addiction Research Center Inventory
(ARCI; Martin et al., 1971) was administered 1 h before
and 2.5 and 5 h after MDMA/placebo administration.
Visual Analog Scales (VASs; Hysek et al., 2011, 2012b)
were administered 1 h before and 0, 0.33, 0.67, 1, 1.5,
2, 2.5, 3, 3.5, 4, 5, 6, 8 and 24 h after MDMA/placebo
administration. The 5-Dimensions of Altered States of
Consciousness Rating Scale (5D-ASC; Studerus et al.,
2010) was used 5 h after MDMA/placebo administration
to retrospectively rate the effects of the drugs.
Emotion recognition task. We used a previously described
Facial Emotion Recognition Task that is sensitive to
MDMA (Bedi et al., 2010). The task was performed 1.5 h
after MDMA/placebo administration during the peak
effects of the drugs. The task included 10 neutral faces
and 160 faces that expressed one of four basic emotions
(i.e. happiness, sadness, anger or fear), with pictures
morphed between 0% (neutral) and 100% in 10% steps.
Two female and two male pictures were used for each
of the four emotions. Stimuli were shown in a
randomized order for 500ms and were then replaced by
the rating screen. The participants had to indicate the
correct emotion. The outcome measure was accuracy.
Adverse effects. Adverse effects were assessed before and
5 and 24 h after MDMA or placebo administration using
the 66-item List of Complaints (Zerssen, 1976). The scale
yields a total adverse effects score, reliably measuring
physical and general discomfort.
Endocrine and pharmacokinetic measures
Blood samples to determine concentrations of catechol-
amines (i.e. NE and epinephrine) were collected at base-
line and 1 and 2 h after MDMA/placebo administration.
Free catecholamine plasma concentrations were deter-
mined using ultraperformance liquid chromatography-
mass spectrometry/mass spectrometry (UPLC-MS/MS;
Dunand et al., 2013). Plasma cortisol and prolactin levels
were measured at baseline and 2 h after MDMA/placebo
administration using radioimmunoassays (Hysek et al.,
2012a). Blood samples for the determination of MDMA,
3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-
methoxymethamphetamine (HMMA) and methylpheni-
date were collected 1 h before and 0, 0.33, 0.67, 1, 1.5, 2,
2.5, 3, 4, 6, 8 and 24 h after MDMA/placebo adminis-
tration. PlasmaMDMA,MDA andHMMA concentrations
were determined using high-performance LC-MS/MS,
as described previously (Hysek et al., 2012c, 2013), and
methylphenidate was added as an additional analyte.
The detection limits were 1 ng/ml for MDMA, MDA,
HMMA and methylphenidate. Interday precision values
(CV) ranged from 3.2 to 8.8%, and interday accuracy
values ranged from 86.8 to 106.4% for all of the analytes.
Statistical and pharmacokinetic analyses
Subjective effects, catecholamine levels and body tem-
perature values were transformed to differences from
baseline. Peak effect (Emax) values were determined for
all repeated measures. Emax values were analysed by
repeated-measures analysis of variance (ANOVA), with
MDMA (MDMA vs. placebo) and methylphenidate
(methylphenidate vs. placebo) as the within-subjects fac-
tors, using STATISTICA 11 (StatSoft, USA). Tukey’s post-
hoc comparisons were performed based on significant
main effects or interactions. Additional ANOVAs were
performed with drug order to exclude carry-over effects.
The criterion for significance was p<0.05. Pharmaco-
kinetic data were analysed using non-compartmental
models. Cmax and the time to maximal plasma concen-
tration (Tmax) were obtained directly from the observed
concentration-time curves. The terminal elimination rate
constant (λz) was estimated by log-linear regression after
semilogarithmic transformation of the data using at least
three data points of the terminal linear phase of the
concentration–time curve. Terminal elimination half-life
(t1/2) was calculated using λz and the equation t1/2= ln2/
λz. The area under the plasma time curve (AUC0−24h)
was calculated using the linear trapezoidal rule.
Results
Pharmacodynamics
Pharmacodynamic peak effects and statistics are shown
in Table 1.
Autonomic effects
MDMA produced significantly higher increases in sys-
tolic blood pressure than methylphenidate (p<0.01,
Fig. 1a), whereas methylphenidate produced significantly
higher increases in heart rate than MDMA (p<0.01;
Fig. 1b). This resulted in similar rate–pressure products
(systolic blood pressure×heart rate) for methylphenidate
or MDMA, indicating that the total haemodynamic re-
sponses to the doses of methylphenidate or MDMA
used in the present study were comparable (Table 1).
Co-administration of methylphenidate and MDMA
produced similar systolic peak pressure increases as
MDMA alone (Fig. 1a) and similar peak increases in
heart rate as methylphenidate alone (Fig. 1b). However,
the rate–pressure product was significantly higher for
methylphenidate–MDMA co-administration compared
with either MDMA or methylphenidate alone (both
p<0.001, Table 1). Methylphenidate, MDMA and the com-
bination all significantly increased body temperature to
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Table 1. Mean±S.E.M. values and statistics of pharmacodynamic changes
Placebo–
placebo
(mean±S.E.M.)
Methylphenidate–
placebo
(mean±S.E.M.)
Placebo–MDMA
(mean±S.E.M.)
Methylphenidate–
MDMA
(mean±S.E.M.)
MDMA Methylphenidate
Methylphenidate×
MDMA
F1,15 P= F1,15 p= F1,15 p=
Subjective effects
Visual Analogue Scale (VAS, %max)
Any drug effect ΔEmax 2.8±1.9 48.9±8.3*** ### 78.0±7.3*** 76.9±8.0*** 107.65 <0.001 10.87 0.005 36.57 <0.001
Drug liking ΔEmax 1.4±1.4 50.0±7.9*** ## 80.2±6.8*** 73.5±8.3*** 81.52 <0.001 12.58 0.003 40.62 <0.001
Drug high ΔEmax 1.1±0.9 45.8±8.4*** ## 76.6±7.7*** 66.1±8.6*** 58.72 <0.001 7.45 0.016 26.68 <0.001
Stimulated ΔEmax 0.8±0.6 53.2±9.0*** # 75.5±8.2*** 77.1±8.0*** 64.89 <0.001 21.28 <0.001 30.75 <0.001
Happy ΔEmax 1.5±1.2 12.5±3.4### 34.9±4.6*** 24.5±4.3*** 48.70 <0.001 0.01 0.940 12.39 0.003
Close to others ΔEmax 0.4±0.3 9.9±2.9## 29.4±4.8*** 23.4±5.0** 35.37 <0.001 0.36 0.556 5.24 0.037
Adjective Mood Rating Scale (AMRS score)
Emotional excitation ΔEmax −0.8±0.5 6.3±1.6*** 3.7±1.5* 5.9±1.4*** 2.58 0.129 23.50 <0.001 4.66 0.047
Well-being ΔEmax 0.3±0.7 1.4±0.5# 5.6±1.3* 4.9±1.6* 10.85 0.005 0.01 0.929 0.31 0.584
Extroversion ΔEmax −0.4±0.3 1.4±0.5 2.5±0.7** 2.5±0.7** 12.08 0.003 2.35 0.146 2.51 0.134
Activity ΔEmax −0.1±0.4 3.3±0.4*** 1.8±0.7 2.1±0.7* 0.41 0.531 10.73 0.005 6.84 0.019
Concentration ΔEmax −0.1±0.3 2.6±0.4**### −0.4±0.6 1.6±0.6# 1.38 0.258 31.30 <0.001 0.88 0.362
Anger ΔEmax 0.3±0.2 0.9±0.3 0.3±0.4 0.8±0.3 0.01 0.935 4.01 0.064 0.01 0.910
Addiction Research Center Inventory (ARCI score)
Amphetamine group ΔEmax 1.25±0.2 4.31±0.6*** 4.88±0.6*** 5.19±0.6*** 21.13 <0.001 16.30 <0.001 11.27 0.004
Benzedrine group ΔEmax 0.63±0.3 3.06±0.6** 1.75±0.6 1.88±0.5 0.00 0.960 11.43 0.004 6.01 0.027
Morphine-benzedrine group ΔEmax 1.13±0.4 3.56±0.8### 8.63±1.1*** 7.75±0.9*** 31.97 <0.001 1.36 0.260 6.28 0.024
Phenobarbital-alcohol group ΔEmax 1.25±0.4 0.81±0.6 2.88±0.7 3.13±0.8 10.85 0.005 0.02 0.891 0.32 0.580
LSD group ΔEmax 0.0±0.1 1.69±0.6* 2.00±0.5* 2.31±0.5** 15.94 0.001 5.65 0.031 2.91 0.108
Altered State of Conciousness Scale (ASC score)
Oceanic boundlessness 0.0±0.0 161.6±103.6## 664.9±150.8*** 517.6±145.9** 27.86 <0.001 0.01 0.922 2.34 0.147
Anxious ego dissolution 0.5±0.5 86.1±33.1 201.8±87.0* 248.8±87.5** 6.01 0.027 10.04 0.006 0.92 0.352
Visionary restructuralization 0.0±0.0 49.5±29.6 199.8±73.1* 192.9±80.31* 8.50 0.011 0.54 0.476 0.61 0.448
All 0.4±0.4 297.2±161.6## 1066.4±272.7*** 959.3±291.4*** 20.50 <0.001 0.51 0.488 1.83 0.196
Emotion recognition
Facial emotion recognition task (accuracy)
Neutral % correct 72.50±5.04 70.00±4.83 70.63±6.49 71.25±4.37 0.01 0.932 0.05 0.823 0.17 0.690
Happy % correct 67.03±2.88 72.97±2.82 71.25±3.82 63.13±3.43# 2.59 0.129 0.28 0.605 20.08 <0.001
Sad % correct 53.28±4.26 62.66±3.11*### 46.41±4.44 51.72±3.84 11.21 0.004 15.52 0.001 1.12 0.307
Anger % correct 64.53±3.16 67.81±3.04 61.41±3.89 58.13±4.80 9.09 0.009 0.00 1.000 2.94 0.107
Fear % correct 56.72±2.65 65.31±2.62*### 49.38±4.17 49.38±3.98 14.50 0.002 4.95 0.042 13.50 0.002
All % correct 62.81±1.46 67.75±1.57**### 59.81±2.53 58.72±2.48* 13.07 0.003 3.87 0.068 12.73 0.003
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similar extents (p<0.01, 0.05 and 0.05 compared with
placebo, respectively; Table 1).
Subjective effects
The combination of methylphenidate and MDMA pro-
duced similar effects as MDMA alone in all of the psycho-
metric measures. This means that methylphenidate did
not enhance the psychotropic effects of MDMA although
it produced partly similar psychoactive effects (Table 1,
Fig. 1, and Supplementary Figs S1–3). MDMA produced
more pronounced and qualitatively different psycho-
tropic effects than methylphenidate. MDMA increased
AMRS ratings of well-being (p<0.05) and extroversion
(p<0.01), whereas methylphenidate did not (Supplemen-
tary Fig. S1a and 1b, respectively). In the ARCI, MDMA
produced significantly higher Morphine–Benzedrine
Group effects (i.e. a measure of euphoria) than methyl-
phenidate (p<0.001; Supplementary Fig. S2c). In the
VASs, MDMA increased all ratings significantly more
than methylphenidate (Supplementary Fig. S3a–f).
MDMA increased ratings of happy (p<0.001) and close
to others (p<0.001), whereas methylphenidate did not.
MDMA also markedly increased the total score
(p<0.001), particularly oceanic boundlessness (p<0.001),
in the 5D-ASC, whereas methylphenidate did not
(Table 1). Conversely, methylphenidate but not MDMA
or the methylphenidate–MDMA combination increased
AMRS ratings of activity (p<0.001) and concentration
(p<0.01; Supplementary Fig. S1d and S1e) and ARCI Ben-
zedrine Group effects (i.e. a measure of intellectual effici-
ency and energy; p<0.01, Supplementary Fig. S2b). In the
ARCI, both MDMA and methylphenidate produced simi-
lar Amphetamine Group effects (both p<0.001 compared
with placebo; Supplementary Fig. S2a).
Effects on emotion recognition
Methylphenidate increased identification accuracy for sad
and fearful faces, reflected by significant main effects
of methylphenidate (F1,15 =15.52, p<0.001 and F1,15=4.95,
p<0.05, respectively) and significant post-hoc tests com-
pared with placebo (both p<0.05; Table 1). In contrast,
MDMA impaired the recognition of negative emotions,
including sadness (F1,15=11.21, p<0.01), anger (F1,15 =9.09,
p<0.01) and fear (F1,15=14.50, p<0.002; Table 1).
Endocrine effects
Peak effects and statistics are shown in Table 1.
Methylphenidate had no effects on the plasma levels of
cortisol, prolactin or NE, but it increased epinephrine
compared with placebo (p<0.05). MDMA increased the
plasma concentrations of cortisol (p<0.001), prolactin
(p<0.001), epinephrine (p<0.001), and NE (p<0.01) com-
pared with placebo. Methylphenidate significantly
reduced the MDMA-induced increase in NE plasmaAu
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levels (F1,15, p<0.03). In contrast, epinephrine concentra-
tions were higher following methylphenidate–MDMA
administration compared with either drug alone.
Adverse effects
The values and statistics for adverse effects are
shown in Table 1. Both methylphenidate and MDMA
produced significant acute (both p<0.001) and sub-
acute (p<0.001 and 0.05, respectively) adverse effects
compared with placebo. When methylphenidate and
MDMA were co-administered, the total acute and sub-
acute adverse effects of both drugs were significantly
higher compared with either drug alone (p<0.01
and 0.001, respectively). Frequently reported acute
adverse effects of methylphenidate, MDMA and methyl-
phenidate–MDMA were dry mouth (n=8, n=13 and
n=15, respectively), lack of appetite (n=8, n=8 and
n=16, respectively), palpitations (n=8, n=4 and n=9, re-
spectively), headache (n=9, n=4 and n=7, respectively),
and nausea (n=7, n=1 and n=5, respectively). No severe
adverse effects were reported.
Pharmacokinetics
Pharmacokinetic data were missing from one subject,
resulting in n=15. The pharmacokinetic parameters for
all of the drugs and metabolites are shown in Table 2.
Cmax, AUC0–24h, and t1/2 values for MDMA and its meta-
bolites MDA and HMMA were not altered by the pre-
treatment with methylphenidate compared with placebo
(Table 2, Fig. 2a, b). However, methylphenidate pre-
treatment prolonged the Tmax of MDMA and MDA
compared with placebo (F1,15=6.79, p<0.02). CYP2D6 ac-
tivity influenced MDMA metabolism. Higher CYP2D6
activity (i.e. lower dextromethorphan/dextrorphan urine
concentration ratios) correlated with lower MDMA
AUC0–24h values (rs =0.53, p<0.04) and higher HMMA
Cmax and AUC0–24h values (rs <−0.61, p<0.02, and
rs <−0.57, p<0.03, respectively). The pharmacokinetic–
pharmacodynamic relationships for the haemodynamic
and psychotropic effects of methylphenidate and
MDMA are shown in Fig. 2c, d, respectively. The effects
of MDMA showed marked clockwise hysteresis, with
substantially smaller dynamic effects at a given plasma
MDMA concentration later in time, suggesting rapid
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Fig. 1. Pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. The values are expressed
as the mean±S.E.M. in 16 subjects. MDMA produced greater increases in systolic blood pressure than methylphenidate (a).
Methylphenidate produced greater increases in heart rate than MDMA (b). Co-administration of methylphenidate and MDMA
produced similar systolic pressure increases as MDMA alone (a) and similar increases in heart rate as methylphenidate alone (b).
However, the rate–pressure product was significantly greater after methylphenidate–MDMA compared with either drug alone
(Table 1). (c) Methylphenidate did not enhance the subjective effects of MDMA although methylphenidate produced subjective
effects when given alone.
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acute pharmacological tolerance. In contrast, the effect–
concentration plots of methylphenidate showed little hys-
teresis, consistent with no relevant acute pharmacological
tolerance.
Discussion
Methylphenidate did not attenuate the pharmaco-
dynamics effects of MDMA as we originally hypothesized
Table 2. Pharmacokinetic parameters of MDMA, MDA, HMMA, and methylphenidate
Cmax (ng/ml) AUC0–24 (ng/ml·h) AUC0−∞ (ng/ml·h) t1/2 (h) tmax (h)
MDMA
Placebo–MDMA 220.1±16.1 2649.4±208.7 3033.9±252.4 7.7±0.4 2.4±0.1
Methylphenidate–MDMA 212.4±9.9 2735.3±166.3 3215.0±256.5 7.7±0.7 3.5±0.4*
MDA
Placebo–MDMA 11.2±0.8 182.3±13.3 294.1±20.8 16.1±1.3 6.5±0.2
Methylphenidate–MDMA 10.8±0.7 176.1±14.4 310.2±53.4 16.5±2.7 7.4±0.2*
HMMA
Placebo–MDMA 78.7±40.0 1016.1±116.1 1275.2±154.4 9.7±0.7 3.6±0.3
Methylphenidate–MDMA 69.1±7.7 973.9±96.4 1259.4±143.8 10.2±1.0 4.2±0.4
Methylphenidate
Methylphenidate–placebo 30.4±2.4 175.4±14.0 – 2.8±0.1 2.3±0.2
Methylphenidate–MDMA 30.6±2.7 175.2±14.7 – 2.8±0.1 2.4±0.2
Values are mean±S.E.M. of 15 healthy subjects. Cmax, maximum plasma concentration; Tmax, time to maximum plasma concentration;
AUC, area under the plasma concentration–time curve. *p<0.05 compared to placebo–MDMA.
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it should. However, methylphenidate did not enhance
any of the psychotropic effects of MDMA, although
methylphenidate produced considerable subjective effects
on its own. The thermogenic effect of methylphenidate–
MDMA was also similar to both drugs alone. In contrast,
the haemodynamic response to methylphenidate–MDMA
was significantly higher compared with MDMA or
methylphenidate alone. Methylphenidate–MDMA also
resulted in more subjective adverse effects and higher
plasma epinephrine concentrations than either drug
alone. From a safety or recreational use perspective, the
findings overall indicate that the combined use of methyl-
phenidate and MDMA would not result in additional
psychoactive effects compared with MDMA alone, but
such a combination would enhance cardiovascular and
adverse effects. No previous studies have assessedmethyl-
phenidate–MDMA interactions. Studies with other psy-
chostimulants showed that maintenance on up to 90mg
methylphenidate either did not alter or increased the
cardiostimulant effects of cocaine and decreased some
of its positive subjective effects (Collins et al., 2006;
Winhusen et al., 2006).
The interactive effects of methylphenidate and MDMA
are pharmacodynamic in nature and are not explained
by pharmacokinetic interactions, as documented in the
present study. MDMA is mostly metabolized by
O-demethylation by CYP2D6 to 3,4-dihydromethamphet-
amine (de la Torre et al., 2012). A minor pathway of
MDMA includes N-demethylation by CYP2B6 and
CYP3A4 to the active metabolite MDA. In the present
study, methylphenidate did not alter the Cmax, AUC
or t1/2 values of MDMA, MDA or HMMA, indicating
that methylphenidate has no effects on MDMA metab-
olism. However, methylphenidate increased the Tmax of
MDMA and MDA, suggesting the delayed absorption of
MDMA. Conversely, MDMA did not alter the pharmaco-
kinetics of methylphenidate, which is metabolized by car-
boxylesterase 1 to inactive ritalinic acid (Sun et al., 2004).
A major limitation of the study is the lack of a
dose–response design. We used only single, mid- to high-
doses of methylphenidate and MDMA. A more complete
characterization of the methylphenidate–MDMA interac-
tion would require testing different doses of both drugs.
Our findings are consistent with the view that DAT
does not critically contribute to the effects of MDMA in
humans. In similar studies in healthy subjects, the psy-
chotropic and autonomic effects of MDMA were reduced
by selective SERT inhibition (Liechti et al., 2000; Liechti
and Vollenweider, 2000) and NET inhibition (Hysek
et al., 2011) and almost completely blocked by combined
SERT/NET inhibition (Hysek et al., 2012d). In monkeys,
a selective DAT inhibitor and methylphenidate did
not alter the acute behavioural or cognitive effects of
MDMA (Verrico et al., 2008; Fantegrossi et al., 2009). In
contrast, the dual DAT/NET inhibitor bupropion reduced
the acute subjective effects of methamphetamine in
humans (Newton et al., 2006). It remains to be tested
whether bupropion alters the acute response to MDMA
in humans. Overall, the available data indicate that the
SERT and NET mediate most of the acute effects of
MDMA, but the role of DA remains unclear.
The present study directly compared the acute clinical
pharmacological effects of methylphenidate and MDMA.
The doses of the drugs used in the present study resulted
in comparable overall haemodynamic responses, reflected
by similar rate–pressure products. MDMA produced
greater increases in blood pressure comparedwithmethyl-
phenidate. Methylphenidate led to greater increases in
heart rate compared with MDMA. The thermogenic re-
sponse to the combination of methylphenidate–MDMA
was similar to the response to either methylphenidate
or MDMA alone. The finding indicates that concomitant
methylphenidate does not enhance the risk of MDMA-
induced hyperthermia.
Both methylphenidate and MDMA produced similar
subjective Amphetamine Group effects in the ARCI.
However, MDMA produced more ‘empathogenic’ mood
effects than methylphenidate, including higher VASs for
drug liking, happiness and closeness to others, and
AMRS scores for well-being and euphoria. MDMA but
not methylphenidate also produced psychedelic and
mind-altering effects in the 5D-ASC. In contrast, methyl-
phenidate but not MDMA enhanced concentration and
activity in the AMRS and produced Benzedrine Group ef-
fects in the ARCI, consistent with higher self-rated intel-
lectual efficiency and energy (Martin et al., 1971) and its
use as a cognitive enhancer (McCabe et al., 2005).
An additional novel finding of the present study is that
methylphenidate enhanced the recognition of fearful and
sad faces. Thus, methylphenidate tended to produce
negative bias in emotional information processing, similar
to the DA/NE releaser D-amphetamine (Hariri et al., 2002;
Wardle et al., 2012). MDMA, in contrast, produced
positive bias, as previously reported (Bedi et al., 2010;
Hysek et al., 2012a), and similar to the 5-HT agonist psi-
locybin (Kometer et al., 2012). Thus, although methylphe-
nidate and MDMA share some amphetamine-type effects,
their effects on the processing of emotional information
are very different. The positive bias in emotion processing
induced by MDMA likely enhances social interaction.
In contrast, a negative bias in emotion processing is ob-
served in patients with depression (Bourke et al., 2010).
Enhanced recognition of negative emotions may con-
tribute to negative drug reactions and psychosis during
methylphenidate treatment, particularly in a negative
social environment and when higher doses are used
(Ross, 2006). The effects of methylphenidate on socio-
emotional cognition should be investigated further
because of its widespread use for the treatment of
attention-deficit/hyperactivity disorder and as a cognitive
enhancer.
Cortisol and prolactin are markers of serotonergic ac-
tivity (Sommers et al., 1994; Seifritz et al., 1996). MDMA
but not methylphenidate increased plasma cortisol and
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prolactin concentrations as expected (Weizman et al.,
1987; Upadhyaya et al., 2003; Dumont and Verkes,
2006). Methylphenidate did not alter MDMA-induced
increases in circulating cortisol or prolactin. MDMA
increased plasma NE levels. Plasma NE mostly represents
an overflow of NE from sympathetic nerves into the circu-
lation (Eisenhofer et al., 1995). Methylphenidate reduced
the MDMA-induced increase in plasma NE, suggesting
that the pharmacodynamic interactive effects of methyl-
phenidate and MDMA are partially attributable to a phar-
macological interaction at the NET. Both methylphenidate
and MDMA increased plasma epinephrine levels, and the
effect was significantly greater when both drugs were
administered together. Circulating epinephrine is mainly
derived from the adrenals (Eisenhofer et al., 1995) and is a
marker of the central stimulation of DA (Volkow et al.,
2003), NE (Kuczenski and Segal, 1997) and 5-HT (Blardi
et al., 2005). Epinephrine lowers peripheral resistance,
resulting in an increase in heart rate. In contrast, NE
increases peripheral resistance, resulting in an increase
in blood pressure and a decrease in heart rate (Allwood
et al., 1963). Thus, the different effects of methylphenidate
and MDMA on heart rate and blood pressure are consist-
ent with their plasma catecholamine releasing profiles.
Plotting the pharmacokinetic–pharmacodynamic re-
lationships for MDMA and methylphenidate revealed a
clinically important difference between the two drugs.
Rapid acute pharmacodynamic tolerance was observed
to the effects of MDMA but not methylphenidate.
Despite the long plasma half-life of MDMA (i.e. 8 h)
and persistent high drug levels in the blood, most phar-
macodynamic drug effects rapidly return to baseline
within 4–6 h. In contrast, the dynamic effects of methyl-
phenidate closely reflected the plasma concentrations of
methylphenidate and are consistent with the plasma half-
life of 3 h. Thus, in the case of MDMA, a long plasma half-
life does not necessarily mean that the actual drug effects
are also long-lasting. The acute tolerance to MDMA likely
reflects its mode of action resulting in a functional de-
pletion of presynaptic monoamine stores so that no
more transmitter can be released, despite high concen-
trations of MDMA.
In conclusion, co-administration of methylphenidate
and MDMA produced pharmacodynamic effects that
were not substantially larger than those of MDMA
alone. No relevant pharmacokinetic interactions between
methylphenidate and MDMA were observed. The effects
of MDMA but not methylphenidate were characterized
by acute pharmacodynamic tolerance. Finally, MDMA
produced positive emotional bias and methylphenidate
produced negative emotional bias in emotion recognition,
and this requires further investigation.
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